The online version of this article (doi:10.1186/1477-7819-10-109) contains supplementary material, which is available to authorized users.
There are no financial or non-financial competing interests to declare in relation to this manuscript.
MN carried out the analysis of data and wrote the manuscript. MS, TW, HT, NY, SM, KW, TG, TO, SF, CK, NY, YR, MM, and MA made the database of patients. All authors read and approved the final manuscript.
The guidelines established by the National Comprehensive Cancer Network do not describe mucinous histology as a clinical factor that should influence the therapeutic algorithm. However, previous studies show conflicting results regarding the prognosis of colorectal mucinous adenocarcinoma. In this study, we described the clinicopathological features of mucinous adenocarcinoma in Japan, to identify optimal therapeutic strategies.
144 patients with mucinous and 2673 with non-mucinous adenocarcinomas who underwent primary resection in two major centers in Yokohama, Japan were retrospectively evaluated for clinicopathological features and treatment factors. A multivariate analysis for overall survival followed by the comparison of overall survival using Cox proportional hazard model were performed.
Patients with mucinous adenocarcinoma had larger primary lesions, higher preoperative CEA levels, a deeper depth of invasion, higher rates of nodal and distant metastasis, and more metastatic sites. A multivariate analysis for overall survival revealed a mucinous histology to be an independent prognostic factor. In the subgroup analysis stratified by stage, Patients diagnosed as StageIII and IV disease had a worse survival in mucinous adenocarcinoma than non-mucinous, while survival did not differ significantly in patients diagnosed as Stage0-II disease. In StageIII, local recurrence in rectal cases and peritoneal dissemination were more frequently observed in patients with a mucinous histology.
Our study indentified that mucinous adenocarcinoma was associated with a worse survival compared with non-mucinous in patients with StageIII and IV disease. In rectal StageIII disease with mucinous histology, additional therapy to control local recurrence followed by surgical resection may be a strategical alternative. Further molecular investigations considering genetic features of mucinous histology will lead to drug development and better management of peritoneal metastasis
Hamilton SR, Aaltonen LA: Pathology and Genetics, Tumours of the Digestive System. In World Health Organization Classification of Tumours. 2000, IARC, Lyon, 3
Safaee A, Moghimi-Dehkordi B, Fatemi SR, Ghiasi S, Nemati-Malek F, Zali MR: Characteristics of colorectal mucinous adenocarcinoma in Iran. Asian Pac J Cancer Prev. 2010, 11: 1373-1375. PubMed
Zhang H, Evertsson S, Sun X: Clinicopathological and genetic characteristics of mucinous carcinomas in the colorectum. Int J Oncol. 1999, 14: 1057-1061. PubMed
Kim DH, Kim JW, Cho JH, Baek SH, Kakar S, Kim GE, Sleisenger MH, Kim YS: Expression of mucin core proteins, trefoil factors, APC and p21 in subsets of colorectal polyps and cancers suggests a distinct pathway of pathogenesis of mucinous carcinoma of the colorectum. Int J Oncol. 2005, 27: 957-964. PubMed
Song GA, Deng G, Bell I, Kakar S, Sleisenger MH, Kim YS: Mucinous carcinomas of the colorectum have distinct molecular genetic characteristics. Int J Oncol. 2005, 26: 745-750. PubMed
Engstrom PF, Arnoletti JP, Benson AB, Chen YJ, Choti MA, Cooper HS, Covey A, Dilawari RA, Early DS, Enzinger PC, Fakih MG, Fleshman J, Fuchs C, Grem JL, Kiel K, Knol JA, Leong LA, Lin E, Mulcahy MF, Rao S, Ryan DP, Saltz L, Shibata D, Skibber JM, Sofocleous C, Thomas J, Venook AP, Willett C: National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology: colon cancer. J Natl Compr Canc Netw. 2009, 7: 778-831. PubMed
Engstrom PF, Arnoletti JP, Benson AB, Chen YJ, Choti MA, Cooper HS, Covey A, Dilawari RA, Early DS, Enzinger PC, Fakih MG, Fleshman J, Fuchs C, Grem JL, Kiel K, Knol JA, Leong LA, Lin E, Mulcahy MF, Rao S, Ryan DP, Saltz L, Shibata D, Skibber JM, Sofocleous C, Thomas J, Venook AP, Willett C: National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology: rectal cancer. J Natl Compr Canc Netw. 2009, 7: 838-881. PubMed
Maksimovic S: Survival rates of patients with mucinous adenocarcinoma of the colorectum. Med Arh. 2007, 61: 26-29. PubMed
Papadopoulos VN, Michalopoulos A, Netta S, Basdanis G, Paramythiotis D, Zatagias A, Berovalis P, Harlaftis N: Prognostic significance of mucinous component in colorectal carcinoma. Tech Coloproctol. 2004, 8 (Suppl 1): 123-125. CrossRef
Edge SB, Byrd DR, Compton CC, Fritz A: AJCC Cancer Staging Manual 7th edn. 2010, AJCC, New York
Galandiuk S, Wieand HS, Moertel CG, Cha SS, Fitzgibbons RJ, Pemberton JH, Wolff BG: Patterns of recurrence after curative resection of carcinoma of the colon and rectum. Surg Gynecol Obstet. 1992, 174: 27-32. PubMed
Compton CC, Fielding LP, Burgart LJ, Conley B, Cooper HS, Hamilton SR, Hammond ME, Henson DE, Hutter RV, Nagle R, Nielsen ML, Sargent DJ, Taylor CR, Welton M, Willett C: Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med. 2000, 124: 979-994. PubMed
Wong RK, Berry S, Spithoff K, Simunovic M, Chan K, Agboola O, Dingle B: Preoperative or postoperative therapy for stage II or III rectal cancer: an updated practice guideline. Clin Oncol (R Coll Radiol). 2010, 22: 265-271. 10.1016/j.clon.2010.03.002. CrossRef
Kurt M, Ozkan L, Yilmazlar T, Ercan I, Zorluoglu A, Memik F, Engin K: Postoperative concomitant chemoradiotherapy in locally advanced rectal cancer. Hepatogastroenterology. 2005, 52: 1411-1415. PubMed
Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J, Fontaumard E, Brachet A, Caillot JL, Faure JL, Poercheron J, Peix JL, François Y, Vignal J, Gilly FN: Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer. 2000, 88: 358-363. 10.1002/(SICI)1097-0142(20000115)88:2<358::AID-CNCR16>3.0.CO;2-O. CrossRefPubMed
Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, Zoetmulder FA: Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003, 21: 3737-3743. 10.1200/JCO.2003.04.187. CrossRefPubMed
Catalano V, Loupakis F, Graziano F, Torresi U, Bisonni R, Mari D, Fornaro L, Baldelli AM, Giordani P, Rossi D, Alessandroni P, Giustini L, Silva RR, Falcone A, D’Emidio S, Fedeli SL: Mucinous histology predicts for poor response rate and overall survival of patients with colorectal cancer and treated with first-line oxaliplatin- and/or irinotecan-based chemotherapy. Br J Cancer. 2009, 100: 881-887. 10.1038/sj.bjc.6604955. PubMedCentralCrossRefPubMed
Leopoldo S, Lorena B, Cinzia A, Gabriella DC, Angela Luciana B, Renato C, Antonio M, Carlo S, Cristina P, Stefano C, Maurizio T, Luigi R, Cesare B: Two subtypes of mucinous adenocarcinoma of the colorectum: clinicopathological and genetic features. Ann Surg Oncol. 2008, 15: 1429-1439. 10.1245/s10434-007-9757-1. CrossRefPubMed
- The clinicopathological features of colorectal mucinous adenocarcinoma and a therapeutic strategy for the disease
- BioMed Central
Neu im Fachgebiet Chirurgie
e.Med Kampagnen-Visual, Mail Icon II